MYL-1401A Efficacy and Safety Comparability Study to Humira®

Psoriasis Clinical Trial

Official title:

Multicenter, Double-Blind, Randomized, 2-Arm, Parallel-Group, Equivalence Study Evaluating Efficacy and Safety Similarity of Mylan Adalimumab (MYL-1401A) Compared With Humira® in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02714322
• Other study ID #: MYL-1401A-3001
• Secondary ID: 2014-003420-46
• Status: Completed
• Phase: Phase 3
• Start date: June 2015
• Est. completion date: March 2017

Study information

• Verified date: March 2022
• Source: Viatris Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To assess the equivalence of MYL-1401A to Humira® with regards to efficacy in subjects with moderate-to-severe chronic plaque psoriasis

Description:

Eligible subjects will be randomly assigned based on predefined stratification factors of weight, geographic region, and presence of psoriatic arthritis:

Randomization is 2:1 to MYL-1401A or Humira®, respectively.

The study will be conducted in the outpatient setting and comprises 3 periods: a screening period of up to 4 weeks, a 52-week treatment period, and a safety follow-up for 8 weeks.

A subject will be considered to have completed the study once they have completed the 52-week treatment period and the 8-week follow-up visit.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 294
• Est. completion date: March 2017
• Est. primary completion date: May 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Subject has signed the informed consent form

2. Subject is aged 18 to 75 years, inclusive, at time of Screening

3. Subject has had moderate-to-severe chronic plaque psoriasis for at least 6 months

• Subject has involved BSA =10%, PASI =12, and sPGA =3 (moderate) at Screening and at Baseline

4. Subject has had stable disease for at least 2 months (i.e. without significant changes as defined by the investigator)

5. Subject is a candidate for systemic therapy

6. Subject has had a previous failure, inadequate response, intolerance, or contraindication to at least 1 conventional antipsoriatic systemic therapy

7. Subject is naïve to adalimumab therapy, approved or investigational

8. For females of childbearing potential, a negative serum pregnancy test during Screening and a negative urine pregnancy test at Baseline

Exclusion Criteria:

1. Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, other skin conditions (e.g. eczema), or other systemic autoimmune disorder inflammatory disease at the time of the screening visit that would interfere with evaluations of the effect of the study treatment on psoriasis

2. Subject has used any of the following medications within specified time periods or will require their use during the study:

• Topical medications within 2 weeks before the end of the screening period

• oral psoralen with ultraviolet A (PUVA) phototherapy and/or ultraviolet B (UVB) phototherapy within 4 weeks before the end of the screening period

• Nonbiologic systemic therapies within 4 weeks before the end of the screening period (e.g. cyclosporine, methotrexate, and acitretin)

• Any prior or concomitant adalimumab therapy, approved or investigational

• Any other investigational agent within 90 days or 5 half-lives of Screening (whichever is longer)

• Any systemic steroid in the 4 weeks before the end of the screening period Note:

Low-potency topical corticosteroids applied to the palms, soles, face, and intertriginous areas are permitted during study participation

3. Subject has received live vaccines during the 4 weeks prior to Screening or has the intention of receiving a live vaccine at any time during the study

4. Subject has a positive test for tuberculosis (TB) during Screening or a known history of active or latent TB, except documented and complete adequate treatment of TB or initiation (>1 month) of adequate prophylaxis of latent TB, with an isoniazid-based regimen

• Subjects with a positive purified protein derivative (PPD) and a history of Bacillus Calmette-Guérin vaccination are allowed with a negative Interferon-? release assays (IGRA)

• Subjects with a positive PPD test without a history of Bacillus Calmette-Guérin vaccination or subjects with a positive or indeterminate IGRA are allowed if they have all of the following:

• No symptoms or signs of active TB, including a negative chest x-ray within 3 months prior to the first dose of study treatment

• Documented history of completion of adequate treatment of TB or initiation (>1 month) of adequate prophylaxis of latent TB, with an isoniazid-based regimen prior to receiving study treatment in accordance with local recommendations

5. Underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious, or gastrointestinal) which, in the opinion of the investigator, significantly immunocompromises the subject and/or places the subject at unacceptable risk for receiving an immunomodulatory therapy

6. Subject has a planned surgical intervention during the duration of the study except those related to the underlying disease and which, in the opinion of the investigator, will not put the subject at further risk or hinder the subject's ability to maintain compliance with study treatment and the visit schedule

7. Subject has an active and serious infection or history of infections as follows:

• Any active infection:

• For which nonsystemic anti-infectives were used within 4 weeks prior to randomization.

• Requiring hospitalization or systemic anti-infectives within 8 weeks prior to randomization

• Recurrent or chronic infections or other active infection that, in the opinion of the investigator, might cause this study to be detrimental to the subject

• Invasive fungal infection or mycobacterial infection

• Opportunistic infections, such as listeriosis, legionellosis, or pneumocystis

8. Subject is positive for human immunodeficiency virus, hepatitis C virus antibody or hepatitis B surface antigen (HBsAg) or is positive for hepatitis B core antibody and negative for HBsAg at Screening

9. Subject has a history of clinically significant hematological abnormalities, including cytopenias (e.g. thrombocytopenia, leukopenia)

10. Subject has severe progressive or uncontrolled, clinically significant disease that in the judgment of the investigator renders the subject unsuitable for the study

11. Subject has history of malignancy within 5 years except adequately treated cutaneous squamous or basal cell carcinoma, in situ cervical cancer or in situ breast ductal carcinoma

12. Subject has active neurological disease such as multiple sclerosis, Guillain-Barré syndrome, optic neuritis, transverse myelitis, or history of neurologic symptoms suggestive of central nervous system demyelinating disease

13. Subject has moderate-to-severe heart failure (New York Heart Association class III/IV)

14. Subject has a history of hypersensitivity to the active substance or to any of the excipients of Humira® or MYL-1401A

15. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation

16. Evidence of alcohol or drug abuse or dependency at the time of Screening, for the 5 years prior to Screening or during the study

17. Subject is unable to follow study instructions and comply with the protocol in the opinion of the investigator

Related Conditions & MeSH terms

• Arthritis, Psoriatic
• Psoriasis

Intervention

Biological:
• MYL-1401A (Adalimumab)
MYL-1401A initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose
• Humira® (Adalimumab)
Humira® initial dose of 80 mg administered sc, followed by 40 mg sc given every other week starting 1 week after the initial dose

Locations

Country	Name	City	State
Bulgaria	Mylan Investigational Site 102	Plovdiv
Bulgaria	Mylan Investigational Site 105	Plovdiv
Bulgaria	Mylan Investigational Site 101	Sevlievo
Bulgaria	Mylan Investigational Site 100	Sofia
Bulgaria	Mylan Investigational Site 103	Sofia
Estonia	Mylan Investigational Site 107	Tallinn
Estonia	Mylan Investigational Site 108	Tallinn
Estonia	Mylan Investigational Site 109	Tallinn
Estonia	Mylan Investigational site 110	Tallinn
Estonia	Mylan Investigational Site 106	Tartu
Estonia	Mylan Investigational SIte 112	Tartu
Hungary	Mylan Investigational Site 127	Budapest
Hungary	Mylan Investigational Site 128	Budapest
Hungary	Mylan Investigational Site 125	Debrecen
Hungary	Mylan Investigational Site 129	Gyula
Hungary	Mylan Investigational Site 126	Szekszárd
Poland	Mylan Investigational Site 131	Bialystok
Poland	Mylan Investigational Site 137	Bialystok
Poland	Mylan Investigational Site 135	Iwonicz-Zdroj
Poland	Mylan Investigational Site 140	Krakow
Poland	Mylan Investigational Site 139	Lodz
Poland	Mylan Investigational Site 133	Olsztyn
Poland	Mylan Investigational Site 138	Poznan
Poland	Mylan Investigational Site 136	Warsaw
Poland	Mylan Investigational Site 130	Wroclaw
Poland	Mylan Investigational Site 132	Wroclaw
Poland	Mylan Investigational Site 134	Wroclaw
Russian Federation	Mylan investigational site 156	Kazan
Russian Federation	Mylan Investigational site 155	Penza
Russian Federation	Mylan Investigational Site 148	Ryazan
Russian Federation	Mylan Investigational Site 149	St. Petersburg
Ukraine	Mylan Investigational site 159	Kharkiv
Ukraine	Mylan investigational site 161	Uzhhorod

Sponsors (2)

Lead Sponsor	Collaborator
Mylan Inc.	Mylan GmbH

Countries where clinical trial is conducted

Bulgaria,  Estonia,  Hungary,  Poland,  Russian Federation,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent improvement in PASI from Baseline		Baseline and Week 12
Secondary	Proportion of subjects showing at least a 75% improvement in PASI (PASI 75 response rate)		Week 12
Secondary	Number of subjects achieving static Physician's Global Assessment (sPGA) responses of clear (0) or almost clear (1)		Week 12